TP53 disruptive mutations lead to head and neck cancer treatment failure through inhibition of radiation-induced senescence

Clinical Cancer Research

Volumn 18, Issue 1, 2012, Pages 290-300

  Skinner, Heath D ^a   Sandulache, Vlad C ^a,b   Ow, Thomas J ^a   Meyn, Raymond E ^a   Yordy, John S ^c   Beadle, Beth M ^a   Fitzgerald, Alison L ^a   Giri, Uma ^a   Ang, K Kian ^a   Myers, Jeffrey N ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METFORMIN; PROTEIN P53; REACTIVE OXYGEN METABOLITE; SHORT HAIRPIN RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; COHORT ANALYSIS; CONTROLLED STUDY; DRUG POTENTIATION; GENE DISRUPTION; GENE FUNCTION; GENE MUTATION; GENE SEQUENCE; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MITOSIS; MUTANT; MUTATIONAL ANALYSIS; NONHUMAN; ONCOGENE; ONCOGENE TP53; OUTCOME ASSESSMENT; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOSENSITIVITY; SENESCENCE; TREATMENT FAILURE; TUMOR XENOGRAFT;

AGING; ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; FLUORESCENT ANTIBODY TECHNIQUE; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOENZYME TECHNIQUES; MICE; MUTATION; NEOPLASM RECURRENCE, LOCAL; RADIATION TOLERANCE; REACTIVE OXYGEN SPECIES; SURVIVAL RATE; TREATMENT FAILURE; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84855443905     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-2260     Document Type: Article

References (51)

1. Jemal A, Bray F, Center MM,Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
2. Agrawal N, Frederick MJ, Pickering CR, Bettegowda C, Chang K, Li RJ, et al. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science 2011;333: 1154-57.
3. Alsner J, Sørensen SB, Overgaard J. TP53 mutation is related to poor prognosis after radiotherapy, but not surgery, in squamous cell carcinoma of the head and neck. Radiother Oncol 2001;59:179-85. (Pubitemid 32452311)
4. Koch WM, Brennan JA, Zahurak M, Goodman SN, Westra WH, Schwab D, et al. p53 mutation and locoregional treatment failure in head and neck squamous cell carcinoma. J Natl Cancer Inst 1996;88: 1580-6. (Pubitemid 26374511)
5. Thames HD, Petersen C, Petersen S, Nieder C, Baumann M. Immunohistochemically detected p53 mutations in epithelial tumors and results of treatment with chemotherapy and radiotherapy.Atreatmentspecific overview of the clinical data. Strahlenther Onkol 2002;178: 411-21. (Pubitemid 34847420)
6. Fallai C, Perrone F, Licitra L, Pilotti S, Locati L, Bossi P, et al. Oropharyngeal squamous cell carcinoma treated with radiotherapy or radiochemotherapy: prognostic role of TP53 and HPV status. Int J Radiat Oncol Biol Phys 2009;75:1053-9.
7. Poeta ML, Manola J, Goldwasser MA, Forastiere A, Benoit N, Califano JA, et al. TP53 mutations and survival in squamous-cell carcinoma of the head and neck. N Engl J Med 2007;357:2552-61. (Pubitemid 350294222)
8. Perrone F, Bossi P, Cortelazzi B, Locati L, Quattrone P, Pierotti MA, et al. TP53 mutations and pathologic complete response to neoadjuvant cisplatin and fluorouracil chemotherapy in resected oral cavity squamous cell carcinoma. J Clin Oncol 2010;28:761-6.
9. Erber R, Conradt C, Homann N, Enders C, Finckh M, Dietz A, et al. TP53 DNA contact mutations are selectively associated with allelic loss and have a strong clinical impact in head and neck cancer. Oncogene 1998;16:1671-9. (Pubitemid 28175048)
10. Williams JR, Zhang Y, Zhou H, Gridley DS, Koch CJ, Russell J, et al. A quantitative overview of radiosensitivity of human tumor cells across histological type and TP53 status. Int J Radiat Biol 2008;84: 253-64. (Pubitemid 351489521)
11. Cuddihy AR, Bristow RG. The p53 protein family and radiation sensitivity: yes or no? Cancer Metastasis Rev 2004;23:237-57. (Pubitemid 38881809)
12. Gupta N, Vij R, Haas-Kogan DA, Israel MA, Deen DF, Morgan WF. Cytogenetic damage and the radiation-induced G1-phase checkpoint. Radiat Res 1996;145:289-98.
13. Kawashima K, Mihara K, Usuki H, Shimizu N, Namba M. Transfected mutant p53 gene increases X-ray-induced cell killing and mutation in human fibroblasts immortalizedwith 4-nitroquinoline 1-oxide but does not induce neoplastic transformation of the cells. Int J Cancer 1995;61:76-9.
14. Strasser A, Harris AW, Jacks T, Cory S. DNA damage can induce apoptosis in proliferating lymphoid cells via p53-independent mechanisms inhibitable by Bcl-2. Cell 1994;79:329-39.
15. Pardo FS, Su M, Borek C, Preffer F, Dombkowski D, Gerweck L, et al. Transfection of rat embryo cells with mutant p53 increases the intrinsic radiation resistance. Radiat Res 1994;140:180-5. (Pubitemid 24347098)
16. Biard DS, Martin M, Rhun YL, Duthu A, Lefaix JL, May E, et al. Concomitant p53 gene mutation and increased radiosensitivity in rat lung embryo epithelial cells during neoplastic development. Cancer Res 1994;54:3361-4. (Pubitemid 24225948)
17. Eriksson D, Stigbrand T. Radiation-induced cell death mechanisms. Tumour Biol 2010;31:363-72.
18. Brown JM, Attardi LD. The role of apoptosis in cancer development and treatment response. Nat Rev Cancer 2005;5:231-7. (Pubitemid 40314954)
19. Vakifahmetoglu H, Olsson M, Zhivotovsky B. Death through a tragedy: mitotic catastrophe. Cell Death Differ 2008;15:1153-62. (Pubitemid 351850968)
20. Roninson IB, Broude EV, Chang BD. If not apoptosis, then what? Treatment-induced senescence and mitotic catastrophe in tumor cells. Drug Resist Updat 2001;4:303-13. (Pubitemid 34456384)
21. Gudkov AV, Komarova EA. The role of p53 in determining sensitivity to radiotherapy. Nat Rev Cancer 2003;3:117-29. (Pubitemid 37328879)
22. Castedo M, Perfettini J-L, Roumier T, Valent A, Raslova H, Yakushijin K, et al. Mitotic catastrophe constitutes a special case of apoptosis whose suppression entails aneuploidy. Oncogene 2004;23:4362-70. (Pubitemid 38850415)
23. Ianzini F, Bertoldo A, Kosmacek EA, Phillips SL, Mackey MA. Lack of p53 function promotes radiation-induced mitotic catastrophe in mouse embryonic fibroblast cells. Cancer Cell Int 2006;6:11.
24. Merritt AJ, Allen TD, Potten CS, Hickman JA. Apoptosis in small intestinal epithelial from p53-null mice: evidence for a delayed, p53- independent G2/M-associated cell death after gamma-irradiation. Oncogene 1997;14:2759-66. (Pubitemid 27313407)
25. Lehmann BD, McCubrey JA, Jefferson HS, Paine MS, Chappell WH, Terrian DM. A dominant role for p53-dependent cellular senescence in radiosensitization of human prostate cancer cells. Cell Cycle 2007; 6:595-605. (Pubitemid 46440434)
26. Yigitbasi OG, Younes MN, Doan D, Jasser SA, Schiff BA, Bucana CD, et al. Tumor cell and endothelial cell therapy of oral cancer by dual tyrosine kinase receptor blockade. Cancer Res 2004;64:7977-84. (Pubitemid 39446932)
27. Sandulache VC, Skinner HD, Ow TJ, Zhang A, Xia X, Luchak JM, et al. Individualizing anti-metabolic treatment strategies for head and neck squamous cell carcinoma based on TP53 mutational status. Cancer. 2011 Jun 30. [Epub ahead of print].
28. Eruslanov E, Kusmartsev S. Identification of ROS using oxidized DCFDA and flow-cytometry. Methods Mol Biol 2010;594:57-72.
29. Rago R, Mitchen J, Wilding G. DNA fluorometric assay in 96-well tissue culture plates using Hoechst 33258 after cell lysis by freezing in distilled water. Anal Biochem 1990;191:31-4.
30. el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993;75:817-25. (Pubitemid 23346378)
31. Sano D, Matsumoto F, Valdecanas DR, Zhao M, Molkentine DP, Takahashi Y, et al. Vandetanib restores head and neck squamous cell carcinoma cells' sensitivity to cisplatin and radiation in vivo and in vitro. Clin Cancer Res 2011;17:1815-27.
32. Verheij M, Bartelink H. Radiation-induced apoptosis. Cell Tissue Res 2000;301:133-42. (Pubitemid 30459860)
33. Catalano A, Rodilossi S, Caprari P, Coppola V, Procopio A. 5-Lipoxygenase regulates senescence-like growth arrest by promoting ROSdependent p53 activation. EMBO J 2005;24:170-9. (Pubitemid 40188474)
34. Macip S, Igarashi M, Fang L, Chen A, Pan Z-Q, Lee SW, et al. Inhibition of p21-mediated ROS accumulation can rescue p21-induced senescence. EMBO J 2002;21:2180-8. (Pubitemid 34516777)
35. Passos JF, Nelson G, Wang C, Richter T, Simillion C, Proctor CJ, et al. Feedback between p21 and reactive oxygen production is necessary for cell senescence. Mol Syst Biol 2010;6:347.
36. Inoue T, Kato K, Kato H, Asanoma K, Kuboyama A, Ueoka Y, et al. Level of reactive oxygen species induced by p21Waf1/CIP1 is critical for the determination of cell fate. Cancer Sci 2009;100:1275-83.
37. Anedda A, Rial E, González-Barroso MM. Metformin induces oxidative stress in white adipocytes and raises uncoupling protein 2 levels. J Endocrinol 2008;199:33-40.
38. Buzzai M, Jones RG, Amaravadi RK, Lum JJ, DeBerardinis RJ, Zhao F, et al. Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res 2007;67: 6745-52. (Pubitemid 47105521)
39. Goodwin WJ. Salvage surgery for patients with recurrent squamous cell carcinoma of the upper aerodigestive tract: when do the ends justify the means? Laryngoscope 2000;110:1-18.
40. Ewald JA, Desotelle JA, Wilding G, Jarrard DF. Therapy-induced senescence in cancer. J Natl Cancer Inst 2010;102:1536-46.
41. Mattera L, Courilleau C, Legube G, Ueda T, Fukunaga R, Chevillard- Briet M, et al. The E1A-associated p400 protein modulates cell fate decisions by the regulation of ROS homeostasis. PLoS Genet 2010;6: e1000983.
42. Wang B, Xiao Z, Ren EC. Redefining the p53 response element. Proc Natl Acad Sci U S A 2009;106:14373-8.
43. Kato S, Han S-Y, Liu W, Otsuka K, Shibata H, Kanamaru R, et al. Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc Natl Acad Sci U S A 2003;100:8424-9. (Pubitemid 36842561)
44. Jordan JJ, Inga A, Conway K, Edmiston S, Carey LA, Wu L, et al. Altered-function p53 missense mutations identified in breast cancers can have subtle effects on transactivation. Mol Cancer Res 2010;8: 701-16.
45. Dearth LR, Qian H, Wang T, Baroni TE, Zeng J, Chen SW, et al. Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss of heterozygosity as an important aspect of p53 status in human cancers. Carcinogenesis 2006;28:289-98. (Pubitemid 46321844)
46. Jung Y-S, Qian Y, Chen X. Examination of the expanding pathways for the regulation of p21 expression and activity. Cell Signal 2010;22:1003-12.
47. Back JH, Rezvani HR, Zhu Y, Guyonnet-Duperat V, Athar M, Ratner D, et al. Cancer cell survival following DNA damage-mediated premature senescence is regulated by mammalian target of rapamycin (mTOR)-dependent inhibition of sirtuin 1. J Biol Chem 2011;286:19100-8.
48. Brady CA, Jiang D, Mello SS, Johnson TM, Jarvis LA, Kozak MM, et al. Distinct p53 transcriptional programs dictate acute DNA-damage responses and tumor suppression. Cell 2011;145:571-83.
49. Jiralerspong S, Palla SL, Giordano SH, Meric-Bernstam F, Liedtke C, Barnett CM, et al. Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol 2009;27:3297-302.
50. Sanli T, Rashid A, Liu C, Harding S, Bristow RG, Cutz J-C, et al. Ionizing radiation activates AMP-activated kinase (AMPK): a target for radiosensitization of human cancer cells. Int J Radiat Oncol Biol Phys 2010;78:221-9.
51. Menendez JA, Cufí S, Oliveras-Ferraros C, Vellon L, Joven J, Vazquez- Martin A. Gerosuppressant metformin: less is more. Aging (Albany NY) 2011;3:348-62.